The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD; ClinicalTrials.gov NCT03036150) and EMPA-KIDNEY studies (NCT03594110) will further assess the renal protective effects of SGLT2 inhibitors in patients with chronic kidney disease (CKD) with or without diabetes. This evidence concerns the gene SLC5A2 and chronic kidney disease.